Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
Featured AnalysisFDA Inspection Front Room Protocol — What to Say and What Not ToXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Ranbaxy’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
CMC AnalysisSalt and Co-Crystal Selection: CMC Documentation of Pharmaceutical Form Decisions in Module 3XGene analysis · Aug 22, 2026Explore CMC Analysis →
FDA 483 SignalInside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptFDA 483 · Aug 22, 2026Open Regulatory Record →
Featured AnalysisPolymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion RiskXGene analysis · Aug 22, 2026Read Article →
Regulatory SignalZhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must KnowIMPORT ALERT · Aug 22, 2026Open Regulatory Record →
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
Featured AnalysisFDA Inspection Front Room Protocol — What to Say and What Not ToXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Ranbaxy’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
CMC AnalysisSalt and Co-Crystal Selection: CMC Documentation of Pharmaceutical Form Decisions in Module 3XGene analysis · Aug 22, 2026Explore CMC Analysis →
FDA 483 SignalInside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptFDA 483 · Aug 22, 2026Open Regulatory Record →
Featured AnalysisPolymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion RiskXGene analysis · Aug 22, 2026Read Article →
Regulatory SignalZhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must KnowIMPORT ALERT · Aug 22, 2026Open Regulatory Record →
Quality Systems / CAPA XGene CMC Intelligence Quality Systems / CAPA OOS, CAPA effectiveness, investigations and quality-risk management. Featured analysis FDA 483 Laboratory Controls — Deep Dive for CMC Scientists OOS Investigation Protocol — The CMC Framework FDA Expects OOS Root Cause Analysis Risk Assessment in GMP Remediation — The ICH Q9 Practical Application Current regulatory intelligence Catalent Indiana LLC FDA 483: 8 Observations at Bloomington, Indiana and the Aseptic/Sterile Manufacturing Pattern Every Sterile Injectable Quality Leader Should Assess Request a GMP / QMS Assessment
Catalent Indiana LLC FDA 483: 8 Observations at Bloomington, Indiana and the Aseptic/Sterile Manufacturing Pattern Every Sterile Injectable Quality Leader Should Assess
